Regenerative Medical Technology Group Inc.

RMTGdata completeness 88%9 fiscal years on file

Data notes: no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'realEstateImpairment'; no data for concept 'dividendsPaid'; no data for concept 'pretaxIncome'

i. The business — what you’d actually own

Figure	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	$437,887¹	$1.53M²	$2.41M³	$4.11M⁴	$5.1M⁴
Net income	−$12.9M⁵	−$5.51M⁶	−$9.81M⁷	−$5.56M⁸	−$7.81M⁸
Operating cash flow	−$9.88M⁹	−$1.11M¹⁰	−$419,199¹¹	$850,699¹²	−$706,519¹²
Capital expenditure	—	$198,428¹³	$385,596¹⁴	$215,419¹⁵	$602,583¹⁵
Free cash flow (derived)	—	−$1.31M¹⁰	−$804,795¹¹	$635,280¹²	−$1.31M¹²
Total debt	—	—	—	—	—
Cash & equivalents	$2.98M¹⁶	$1.65M¹⁷	$530,540¹⁷	$1.17M¹⁸	$956,718¹⁸
Diluted shares	11.5M	12.2M	12.4M	12.5M	12.6M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$27.5

your share of equity

Profit it earned you last year

−$6.18

Free cash flow it threw off

−$1.04

Debt you’d be carrying

—

10 shares is a claim on −$27.5 of net worth that earned you −$6.18 and generated −$1.04 of cash last year.

iii. Is this a good business?

Moat signal · return on equity

— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →

Management signal · capital allocation

+10% shares · 5y

Share count is up 10% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.5.0

DCF · Growth Exit 10Y

not applicable

3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)

DCF · Growth Exit 5Y

not applicable

3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts

10-K · period ending 2021-12-31 · accession 0001213900-23-029942 (Revenues)
10-K · period ending 2022-12-31 · accession 0001213900-24-032991 (Revenues)
10-K · period ending 2023-12-31 · accession 0001213900-25-032016 (Revenues)
10-K · period ending 2024-12-31 · accession 0001213900-26-056841 (Revenues)
10-K · period ending 2021-12-31 · accession 0001213900-23-029942 (NetIncomeLoss)
10-K · period ending 2022-12-31 · accession 0001213900-24-032991 (NetIncomeLoss)
10-K · period ending 2023-12-31 · accession 0001213900-25-032016 (NetIncomeLoss)
10-K · period ending 2024-12-31 · accession 0001213900-26-056841 (NetIncomeLoss)
10-K · period ending 2021-12-31 · accession 0001213900-23-029942 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2022-12-31 · accession 0001213900-24-032991 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2023-12-31 · accession 0001213900-25-032016 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2024-12-31 · accession 0001213900-26-056841 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2022-12-31 · accession 0001213900-24-032991 (PaymentsToAcquirePropertyPlantAndEquipment)
10-K · period ending 2023-12-31 · accession 0001213900-25-032016 (PaymentsToAcquirePropertyPlantAndEquipment)
10-K · period ending 2024-12-31 · accession 0001213900-26-056841 (PaymentsToAcquirePropertyPlantAndEquipment)
10-K · period ending 2021-12-31 · accession 0001213900-22-024049 (CashAndCashEquivalentsAtCarryingValue)
10-K · period ending 2022-12-31 · accession 0001213900-24-032991 (CashAndCashEquivalentsAtCarryingValue)
10-K · period ending 2024-12-31 · accession 0001213900-26-056841 (CashAndCashEquivalentsAtCarryingValue)